Table 4. Datasets used to test the model.
| Country | Sample size | No. of surveys | Baseline prevalence | Drug used | Number of years of intervention (years) | Frequency of intervention | Model tested | Ref. | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Follow-up | A. lumbricoides | T. trichiura | Hookworms | |||||||
| Viet Nam | 210–261 | 1 | 5 | 30% | 29% | 76% | ALB | 1–6 | 2/year | OM-SM1-SM2 | [10, 15] |
| Uganda | 1423 | 1 | 3 | 2% | 2% | 59% | ALB | 1–3 | 1/year | OM-SM1-SM2 | [5] |
| Zambia | 490 | 1 | 2 | 22% | 0 | 7.8% | ALB+IVR | 1.5 | 1/year | SM1-SM2 | [16] |
| Lao PDR | 2885 | 1 | 1 | 61% | 43% | 19% | ALB | 2 | 2/year | SM1-SM2 | [17] |
| Myanmar, Pin Lung | 250 | 1 | 1 | 23% | 3% | 5% | ALB | 5 | 2/year | SM1-SM2 | [18–19] |
| Myanmar Phhyu | 250 | 1 | 1 | 50% | 55% | 10% | ALB | 5 | 2/year | SM1-SM2 | [18–19] |
| Myanmar, Nyangdone | 250 | 1 | 1 | 63% | 88% | 0% | ALB | 5 | 2/year | SM1-SM2 | [18–19] |
| Myanmar, Meik | 250 | 1 | 1 | 58% | 84% | 12% | ALB | 5 | 2/year | SM1-SM2 | [18–19] |
| UR Tanzania | 1192 | 1 | 1 | 98% | 90% | 97% | ALB+IVR | 13 | 1/year | SM1-SM2 | [20] |
| Nepal | 711 | 1 | 1 | 22% | 19% | 64% | ALB | 2 | 1/year | SM1-SM2 | [21] |
| India, A. Pradesh | 217 | 1 | 1 | 73% | 67% | 0 | ALB | 0.75 | 1/year | SM1-SM2 | [22] |
| India, W. Bengala | 126 | 1 | 2 | 54% | 0 | 0 | ALB | 0.5–1 | 2/year | SM2 | [23] |
| India, Tamil Nadu | 325 | 1 | 2 | 55% | 17% | 5% | ALB+DEC | 1–2 | 1/year | SM2 | [24] |
| Cambodia, Achen | 50 | 1 | 1 | 25% | 2% | 55% | MEB | 5 | 1/year | SM2 | [25] |
| Cambodia, Chartnol | 50 | 1 | 1 | 10% | 2% | 46% | MEB | 5 | 1/year | SM2 | [25] |
| Cambodia, Sambock | 50 | 1 | 1 | 16% | 2% | 45% | MEB | 5 | 1/year | SM2 | [25] |
| Cambodia, Srekhoeun | 50 | 1 | 1 | 14% | 2% | 50% | MEB | 5 | 1/year | SM2 | [25] |
| Cambodia, Sdau | 50 | 1 | 1 | 51% | 2% | 86% | MEB | 5 | 1/year | SM2 | [25] |
| Cambodia, Koh Sneg | 50 | 1 | 1 | 34% | 2% | 55% | MEB | 5 | 1/year | SM2 | [25] |
| Cambodia, K. Chan Tuk | 50 | 1 | 1 | 70% | 2% | 67% | MEB | 5 | 1/year | SM2 | [25] |
| Seychelles, children | 1058 | 1 | 2 | 18% | 53% | 6% | MEB | 5 | 2/year | SM2 | [26] |
| Seychelles,women | 338 | 1 | 1 | 10% | 36% | 9% | MEB | 2 | 2/year | SM2 | [26] |
| Bangladesh | 223 | 1 | 1 | 45% | 56% | 73% | ALB | 0.5 | 1/year | SM2 | [27] |
| Oman | 860 | 1 | 5 | 40% | 0 | 0.5% | ALB | 1–5 | 1/year | SM2 | [28] |
| Ghana | 1011 | 1 | 2 | 87% | NA | NA | ALB | 1–2 | 2/year | SM2 | [29] |
| Sri Lanka | 177 | 1 | 5 | 84% | 85% | 72% | MEB | 1–6 | 2/year | SM2 | [30] |
| 26 | 45 | ||||||||||
ALB, albendazole; MEB = mebendazole; IVR, ivermectin; DEC, diethylcarbamazine OM, original model; SM1, Simplified Model 1; SM2, Simplified Model 2